Medtech

Company Events

Interviews

Vantage logo

Novo adds weight to its obesity goals

Analysts see semaglutide helping Novo Nordisk to beat its sales target in obesity, but the company has bigger ambitions for earlier projects.

Evaluate Omnium

Evaluate Omnium
Our Products
Evaluate Omnium

Evaluate Omnium is the first and only solution on the market that provides a complete, dynamic view of development risk and commercial return, while also addressing the information gaps that lead to unproductive portfolio investments. The result is 4 times greater accuracy when predicting which Phase I assets will reach the market and a 21% accuracy improvement when predicting commercial potential for Phase I assets, compared to calculations made based on industry average benchmarks. 

Evaluate Vantage Homepage